RecruitingNCT03647098
Survival Outcomes of Lung Cancer
Survival Outcomes for Lung Cancer
Sponsor
Hunan Province Tumor Hospital
Enrollment
20,000 participants
Start Date
Aug 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This is a prospective study to analyze the survival outcomes of different groups about lung cancer patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This trial is collecting information about survival outcomes for patients with lung cancer who are receiving treatment, to better understand which factors and treatments lead to better results.
**You may be eligible if...**
- You are 18 years old or older
- You have been diagnosed with lung cancer confirmed by a biopsy or lab test
- You are in reasonably good physical condition (able to care for yourself and do light activity)
- Your expected survival is at least 12 weeks
- You have measurable cancer visible on imaging scans
- You have adequate blood counts and organ function
- You understand the study and are able to give informed consent
**You may NOT be eligible if...**
- You are unable to understand or agree to participate in the study
- You have very poor overall health
- You have had certain prior treatments that disqualify you per study criteria
- Your organ function (blood, liver, kidneys) is not adequate
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTreatment
Treatment decisions guided by molecular profiling and clinical judgment of principal investigators
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03647098
Related Trials
Holistic Acupuncture for Patients With Chemotherapy Induced Nausea
NCT072011941 location
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
NCT0384805221 locations
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT0605169512 locations
A Clinico-biological Database of Lung Cancers
NCT033878651 location
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
NCT058005871 location